DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Recommendations

Info

Cardiovascular system (Cont.):opioids and, 496–497oxygen inhalation and, 559platelet-activating factor and, 954serotonin and, 340–341thyroid hormones and, 1140–1141vasopressin and, 708Cardioversion, 823, 824tCardioverter/defibrillator, indicationsfor, 823CARDIZEM (diltiazem), 762t, 831Carmoterol, 292f, 294Carmustine, 1668t–1670t, 1686adverse effects and side effects of,1821in dermatology, 1821extramedullary toxicity of, 1682tmechanism of action of, 1820tCarnitineas antidote, 86tdeficiency syndrome, systemic,102t, 113β-Carotene, 1813Maximum RecommendedTherapeutic Dose, 1813Carperitide, 696Carrier-mediated diffusion, 674Carrier-mediated membranetransport, 19Carteolol, as antihypertensive agent,774tCarvedilol, 312f, 329as antihypertensive agent, 774t,780–781for heart failure, 801pharmacokinetics of, 1820tCARVERJECT (alprostandil), forimpotence, 952CASODEX (bicalutamide), 1765Caspofungin acetate, 1583–1584CASTELLANI PAINT MODIFIED (antifungalcombination), 1817Castor oil, 1334Castrationmedical, 1763surgical, 1763CATAFLAM (diclofenac), 987Cataracts, 1777corticosteroid therapy-related, 1227steroid-related, 1792Catecholaminergic polymorphicventricular tachycardia(CPVT), 818Catecholaminesangiontensin II and, 729Catecholamines (Cont.):in central nervous system, 382–384dopamine and, 355endogenous, 282–289monoamine oxidase and, 200refractoriness to, 209–210release, 199angiontensin II and, 729storagae, 196–199synthesis, 194–196termination of actions of, 200–201Catechol-O-methyltransferase(COMT), 138catecholamine termination and, 200Catechol-O-methyltransferase(COMT) inhibitors, forparkinsonism, 617–618Cathartics, 85, 1328–1336Causative polymorphism, 153Caveolac, 17Caveolin, 17CCR5. See Chemokine receptor 5(CCR5)CECLOR (cefaclor), 1494t, 1496tCefaclorantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tCefadroxilchemistry of, 1494tdosage and dosage forms of, 1494tCefamandolechemistry of, 1494tdosage and dosage forms of, 1494tCefazolinantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tpharmacokinetics of, 1820tCefdinir, pharmacokinetics of,1821tCefepimechemistry of, 1494tdosage and dosage forms of, 1494tpharmacokinetics of, 1821tCefixime, for gonococcal urethritis,1842tCEFIZOX (ceftizoxime), 1494tCEFOBID (cefoperazone), 1494tCefonicidchemistry of, 1494tdosage and dosage forms of, 1494tCefoperazonechemistry of, 1494tdosage and dosage forms of, 1494tCeforanidechemistry of, 1494tdosage and dosage forms of, 1494tCEFOTAN (cefotetan), 1494t, 1496tCefotaxime, antibacterial spectrum of,1496tCefotetanantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tfor pelvic inflammatory disease,1842tCefoxitinantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tfor pelvic inflammatory disease,1842tCefpodoxime proxetilchemistry of, 1494tdosage and dosage forms of, 1494tCeftazidimeantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tpharmacokinetics of, 1821tCEFTIN (cefuroxime axetil), 1494t,1496tCeftizoximechemistry of, 1494tdosage and dosage forms of, 1494tCeftriaxoneantibacterial spectrum of, 1496tfor chancroid, 1842tchemistry of, 1494tdosage and dosage forms of, 1494tfor gonococcal urethritis, 1842tfor pelvic inflammatory disease,1842tpharmacokinetics of, 1822tCefuroximeantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tCefuroxime axetilchemistry of, 1494tdosage and dosage forms of, 1494tCELEBREX (celecoxib), 964–965, 991Celecoxib, 964–965, 991absorption, 991adverse effects and side effects of,991arrhythmias caused by, 832in cancer prevention, 972–973compared to aspirin, 970t2009INDEX
2010INDEXCelecoxib (Cont.):COX isoform selectivity, 962fdistribution of, 991dosage and administration of, 970telimination, 991pharmacokinetics of, 970t, 991,1822tpharmacology of, 962fplama binding of, 1822tplasma pharmacokinetics of, 962fstructure of, 991therapeutic uses of, 970t, 991Celiac ganglion, 173fCeliprolol, 312f, 329–330Cell-based screening, in drugdevelopment, 4CELLCEPT (mycophenolate mofetil),1822–1823Cell cycle, in neoplastic disease,1671–1673Cell membranescarrier-mediated transport across, 19characteristics of, 17composition of, 17electrolytes and transport across,18–19facilitated diffusion across, 19passive flux across, 18permeability of, 17pH and transport across, 18–19in pharmacokinetics, 17–19, 18fCellular assays, 154Cellulitis, 1817orbital, 1780–1781CENESTIN (conjugated estrogens), 1839tCentrally acting adrenergic agents as,antihypertensive agents, 774tCentral nervous system (CNS)action of drugs in, 390–393adrenocorticosteroids and, 1221amino acids in, 376amphetamines and, 298angiotensin II and, 729aspartate in, 379–380barbiturates and, 469–472benzodiazepines and, 460beta-adrenergic receptor antagonistsand, 317cannabinoids in, 388carbon dioxide and, 562cell signaling in, 373–376depressants, 390–392, 654–657distribution of drugs and, 25dopamine and, 355–356drug discovery, 393Central nervous system (CNS) (Cont.):drug interactions, 392–393eicosanoids and, 951epinephrine and, 285ethanol and, 633–635fentanyl and, 507GABA in, 376–379glutamate in, 379–380glycine in, 379histamine and, 384–388, 915H 1receptor antagonists and,919–920integrative chemical communicationin, 366–371lipid mediators in, 389–390meperidine and, 503–505methadone and, 508muscarinic antagonists and, 230,233–234neuromuscular blocking agents and,261–262neurotransmitter receptor-effectorcoupling in, 371–372nicotine and, 271nitric oxide in, 390organizational principles of,363–366plasticity of, 366repair of, 366serotonin and, 341–342stimulants, 392supportive cells in, 365synaptic transmission in, 373–376transmitter interactions, 393vasopressin and, 708Central nervous system depressants,654–657Central neurotransmitters, 376–390Cephalexinantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tpharmacokinetics of, 29, 1822tCephalosporinsantibacterial spectrum of, 1496tbacterial resistance to, 1481–1483,1493, 1496chemistry of, 1494tfor deep cutaneous infections, 1817dosage and dosage forms of, 1494tdrug interactions with, 1529first-generation, 1494t, 1496t, 1497fourth-generation, 1494t, 1496t,1498–1499general features of, 1496–1497Cephalosporins (Cont.):mechanism of action of, 1478–1481second-generation, 1494t, 1496t,1497therapeutic uses of, 1499third-generation, 1494t, 1496t,1497–1498Cephalothinantibacterial spectrum of, 1496tchemistry of, 1494tdosage and dosage forms of, 1494tCEPTA (ceftazidime), 1496tCerebellum, 364alpha adrenergic receptors in, 203tCerebral cortex, 363–364Cerebral edema, corticosteroids for,1234Cerebrospinal fluid (CSF)distribution of drugs and, 25penicillin distribution of, 1485Cerebrospinal fluid (CSF) barrierintrathecal injection and, 22transporters and, 116Cerebrovascular disease, 877and dyslipidemia treatment, 890risk assessment, 885–887Cerivastatin, 896drug interactions with, 110Certolizumab, 994tCERVAGEM (gemeprost), 1837Cervical cancer, drugs for,1668t–1670tCervical ganglia, 173fCervical ripening, 1849–1850prostaglandin E 2for, 952Cervicitis, 1842tCERVIDIL (dinoprostone), 1849Cestode infections, 1447–1448Cetirizine, 921t, 924, 1816pharmacokinetics of, 1816t, 1823tCETP. See Cholesteryl ester transferprotein (CETP)Cetrorelix, 1119t, 1843structure of, 1764tCETROTIDE (cetrorelix), 1119t, 1764t,1843Cetuximab, 1734, 1745, 1746tabsorption, 1736adverse effects and side effects of,1737chemistry, 1736distribution of, 1736dosage and administration of, 1747telimination, 1736mechanism of action of, 1736
Page 2 and 3:
Goodman & Gilman’sThe Pharmacolog
Page 4 and 5:
Goodman & Gilman’sThe Pharmacolog
Page 6 and 7:
Material from the disk that accompa
Page 8 and 9:
This page intentionally left blank
Page 10 and 11:
viiiCONTENTS22. Treatment of Centra
Page 12 and 13:
Page 14 and 15:
xiiCONTRIBUTORSBruce A. Chabner, MD
Page 16 and 17:
xivCONTRIBUTORSJonathan M. Meyer, M
Page 18 and 19:
xviCONTRIBUTORSRobert H. Tukey, PhD
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
4SECTION IGENERAL PRINCIPLESbegan i
Page 30 and 31:
6SECTION IGENERAL PRINCIPLESTARGETS
Page 32 and 33:
its mission cannot possibly be acco
Page 34 and 35:
10SECTION IGENERAL PRINCIPLESHMG-Co
Page 36 and 37:
12SECTION IGENERAL PRINCIPLESit to
Page 38 and 39:
14SECTION IGENERAL PRINCIPLESviolat
Page 40 and 41:
16SECTION IGENERAL PRINCIPLESyears.
Page 42 and 43:
18SECTION IGENERAL PRINCIPLESDRUGDO
Page 44 and 45:
20SECTION IGENERAL PRINCIPLEScompou
Page 46 and 47:
22SECTION IGENERAL PRINCIPLESgroups
Page 48 and 49:
24SECTION IGENERAL PRINCIPLESphysic
Page 50 and 51:
26SECTION IGENERAL PRINCIPLESdivers
Page 52 and 53:
28SECTION IGENERAL PRINCIPLESphase
Page 54 and 55:
30SECTION IGENERAL PRINCIPLESDivisi
Page 56 and 57:
32SECTION IGENERAL PRINCIPLESconsis
Page 58 and 59:
34SECTION IGENERAL PRINCIPLEStherap
Page 60 and 61:
36SECTION IGENERAL PRINCIPLESMainte
Page 62 and 63:
38SECTION IGENERAL PRINCIPLESThe ne
Page 64 and 65:
Page 66 and 67:
42 signaling compounds are termed a
Page 68 and 69:
44 receptors, but because the endog
Page 70 and 71:
46 ligand-receptor complex, LR*. Th
Page 72 and 73:
48 agonist plus an effective concen
Page 74 and 75:
50SECTION IGENERAL PRINCIPLESPRESCR
Page 76 and 77:
52 constrained by compartmentation
Page 78 and 79:
54A. Activation by Ligand Binding o
Page 80 and 81:
56 Second MessengersSECTION IGENERA
Page 82 and 83:
58 markedly stimulates Ca 2+ flux,
Page 84 and 85:
60 voltage-gated (Jegla et al., 200
Page 86 and 87:
62SECTION IA(a) UnligandedreceptorI
Page 88 and 89:
64 from the complex allowing the p5
Page 90 and 91:
66 upon binding ligand. Other membe
Page 92 and 93:
68 FADD/TRAF2, and caspase 8, which
Page 94 and 95:
70 of cyclic GMP are also increased
Page 96 and 97:
72 Vo NK, Gettemy JM, Coghlan VM. I
Page 98 and 99:
74100ADeathSECTION I% of Population
Page 100 and 101:
76SECTION IGENERAL PRINCIPLESisofor
Page 102 and 103:
78SECTION IGENERAL PRINCIPLESantago
Page 104 and 105:
80SECTION IGENERAL PRINCIPLESarrhyt
Page 106 and 107:
82SECTION IGENERAL PRINCIPLESThe in
Page 108 and 109:
84SECTION IGENERAL PRINCIPLESGastri
Page 110 and 111:
86SECTION IGENERAL PRINCIPLESTable
Page 112 and 113:
Page 114 and 115:
90TherapeuticeffectMetabolismTExcre
Page 116 and 117:
92Clearance organs(liver, kidney)Co
Page 118 and 119:
94Passive transport (downhill trans
Page 120 and 121:
96SECTION IGENERAL PRINCIPLESNoncom
Page 122 and 123:
Table 5-1Regulation of Transporter
Page 124 and 125:
100ExtracellularSECTION IGENERAL PR
Page 126 and 127:
Table 5-2Families in the Human Solu
Page 128 and 129:
Table 5-3The ATP Binding Cassette (
Page 130 and 131:
Table 5-4ABC Transporters Involved
Page 132 and 133:
108SECTION IGENERAL PRINCIPLESIn th
Page 134 and 135:
110SECTION IGENERAL PRINCIPLESthe u
Page 136 and 137:
112SECTION IGENERAL PRINCIPLESOC +B
Page 138 and 139:
114SECTION IGENERAL PRINCIPLEStrans
Page 140 and 141:
116SECTION IGENERAL PRINCIPLESincre
Page 142 and 143:
118SECTION IGENERAL PRINCIPLESHaseg
Page 144 and 145:
120SECTION IGENERAL PRINCIPLESmulti
Page 146 and 147:
Page 148 and 149:
124SECTION IGENERAL PRINCIPLESconst
Page 150 and 151:
126SECTION IGENERAL PRINCIPLESorall
Page 152 and 153:
Table 6-2Major Reactions Involved i
Page 154 and 155:
130SECTION IGENERAL PRINCIPLESco-ad
Page 156 and 157:
132SECTION IGENERAL PRINCIPLESreact
Page 158 and 159:
134SECTION IGENERAL PRINCIPLESSN-38
Page 160 and 161:
136SECTION IGENERAL PRINCIPLESnon-c
Page 162 and 163:
Table 6-4Indications and Unwanted S
Page 164 and 165:
140SECTION IGENERAL PRINCIPLESsyndr
Page 166 and 167:
142SECTION IGENERAL PRINCIPLESthe t
Page 168 and 169:
Page 170 and 171:
146SECTION IGENERAL PRINCIPLESstres
Page 172 and 173:
148SECTION IGENERAL PRINCIPLESsubst
Page 174 and 175:
150SECTION IGENERAL PRINCIPLESEthni
Page 176 and 177:
152Monogenic traitMultigenic traitS
Page 178 and 179:
154SECTION IGENERAL PRINCIPLESlikel
Page 180 and 181:
15625060Common genetic formSECTION
Page 182 and 183:
158AgeneCYP3A5*1 allele123456789101
Page 184 and 185:
Table 7-3Examples of Genetic Polymo
Page 186 and 187:
162warfarinCYP2C9hydroxywarfarin5SE
Page 188 and 189:
164SECTION IGENERAL PRINCIPLESin a
Page 190 and 191:
166SECTION IGENERAL PRINCIPLESBIBLI
Page 192 and 193:
168SECTION IGENERAL PRINCIPLESRosne
Page 194 and 195:
Page 196 and 197:
172 regulation of sacral parasympat
Page 198 and 199:
174 third lumbar segment. The axons
Page 200 and 201:
176 ganglia, the ratio of pregangli
Page 202 and 203:
Table 8-1Responses of Effector Orga
Page 204 and 205:
Table 8-1Responses of Effector Orga
Page 206 and 207:
182 While these criteria are applic
Page 208 and 209:
184 those vesicles in close proximi
Page 210 and 211:
186HemicholiniumAcCoA + CholineChol
Page 212 and 213:
188 in transmitter release comes fr
Page 214 and 215:
190 Subtypes of Nicotinic Acetylcho
Page 216 and 217:
Table 8-3Characteristics of Muscari
Page 218 and 219:
194 and inhibition of excitable mem
Page 220 and 221:
196SECTION IINEUROPHARMACOLOGYcorre
Page 222 and 223:
Table 8-5Characteristics of Plasma
Page 224 and 225:
200 by activation of β 2adrenergic
Page 226 and 227:
202SECTION IIHOHOCH 3 OHOHOHHO H OH
Page 228 and 229:
Table 8-6Characteristics for Adrene
Page 230 and 231:
Table 8-7Representative Agents Acti
Page 232 and 233:
208α 1A α 2A β 1NH 2NH 2NH 2SECT
Page 234 and 235:
210 uncoupling of G-protein signali
Page 236 and 237:
212 and atenolol, which antagonize
Page 238 and 239:
214 to inhibit its own release. NPY
Page 240 and 241:
216 Furchgott RF. Endothelium-deriv
Page 242 and 243:
218 Nucleotides as Regulators of Ce
Page 244 and 245:
220 M 1through M 5muscarinic recept
Page 246 and 247:
222 difficult to observe with admin
Page 248 and 249:
224 The difficulty in developing su
Page 250 and 251:
226 neurotransmitter release, the p
Page 252 and 253:
228 parasympathetic postganglionic
Page 254 and 255:
230 sympathetic cholinergic fibers,
Page 256 and 257:
Table 9-3Muscarinic Receptor Antago
Page 258 and 259:
234 efficient, resulting in the del
Page 260 and 261:
236 Chapple C, Khullar V, Gabriel Z
Page 262 and 263:
Page 264 and 265:
240 In the 1950s, a series of aroma
Page 266 and 267:
242 tertiary amine physostigmine ex
Page 268 and 269:
Table 10-1Chemical Classification o
Page 270 and 271:
246 The sites of action of anti- Ch
Page 272 and 273:
248 tolerance reassessments, and re
Page 274 and 275:
250 animals after long- term exposu
Page 276 and 277:
252 When the diagnosis of myastheni
Page 278 and 279:
254 Gallo MA, Lawryk NJ. Organic ph
Page 280 and 281:
256 the inhibitory amino acids (γ-
Page 282 and 283:
258 abundance in muscle, along with
Page 284 and 285:
260 and the remainder of the muscle
Page 286 and 287:
262SECTION IINEUROPHARMACOLOGYmyeli
Page 288 and 289:
Table 11-2Classification of Neuromu
Page 290 and 291:
266 Preventing Trauma During Electr
Page 292 and 293:
268 reduced renal function (pancuro
Page 294 and 295:
270 that are selective for M 1musca
Page 296 and 297:
272 and its metabolites are elimina
Page 298 and 299:
274 gastric emptying. Although the
Page 300 and 301:
276 Volle RL. Nicotinic ganglion-st
Page 302 and 303:
278Adrenergic AgonistsDirect-acting
Page 305:
280SECTION IITable 12-1Chemical Str
Page 308 and 309:
282 when both types of receptors ar
Page 310 and 311:
284 falls (epinephrine reversal). A
Page 312 and 313:
286 increase of 20-30% in oxygen co
Page 314 and 315:
288 Therapeutic Uses and Status. NE
Page 316 and 317:
290 may occur, particularly in pati
Page 318 and 319:
292HONOHHNH 3 COCOOHNHC(CH 3 ) 3HOH
Page 320 and 321:
294 agonist that has twice the pote
Page 322 and 323:
296 these receptors is high, althou
Page 324 and 325:
298 CNS. Amphetamine is one of the
Page 326 and 327:
300 treatment of attention-deficit/
Page 328 and 329:
302 syndrome and idiopathic autonom
Page 330 and 331:
304 transient or may respond to adj
Page 332 and 333:
306Alkylating agentCH 3OCH 2 CHNCH
Page 334 and 335:
308 Syncopal episodes also have occ
Page 336 and 337:
310 ingestion of tyramine-containin
Page 338 and 339:
312OOOOHHNOOHHNOBISOPROLOLBETAXOLOL
Page 340 and 341:
314 Billman, 2000; Brodde and Miche
Page 342 and 343:
316 The β receptors mediate activa
Page 344 and 345:
318 treatment for patients with all
Page 346 and 347:
320 for an individual patient shoul
Page 349:
322SECTION IINEUROPHARMACOLOGYTable
Page 353:
Page 357 and 358:
326 nadolol is its relatively long
Page 359 and 360:
328 or membrane-stabilizing activit
Page 361 and 362:
330 and possibly papaverine-like re
Page 363 and 364:
332 Gupta S, Wright HM. Nebivolol:
Page 365 and 366:
Page 367 and 368:
336SECTION IINEUROPHARMACOLOGYNH 2N
Page 369:
Table 13-1Serotonin Receptor Subtyp
Page 372 and 373:
340SECTION IINEUROPHARMACOLOGY5-HT
Page 374 and 375:
Table 13-3Some Actions of 5-HT in t
Page 376 and 377:
344 suppressant in the management o
Page 378 and 379:
346HNHNSECTION IICH 2H 3 CNHSO 2 CH
Page 380 and 381:
Table 13-6Natural and Semisynthetic
Page 382 and 383:
350 mCPP, an active metabolite of t
Page 384 and 385:
352 Oby AADC, the same enzyme that
Page 386 and 387:
354ND1 receptor familyD2 receptor f
Page 388 and 389:
356SECTION IINEUROPHARMACOLOGYMesoc
Page 390 and 391:
358 receptor agonist and a weak D 1
Page 392 and 393:
360 Delgado PL, Charney DS, Price L
Page 394 and 395:
Page 396 and 397:
364 system and integrate somatic an
Page 398 and 399:
366 from the bloodstream into the b
Page 400 and 401:
368A Ion channels α 1 subunits for
Page 402 and 403:
Table 14-1Subtypes of Ca 2+ Channel
Page 404 and 405:
372SECTION IINEUROPHARMACOLOGYselec
Page 406 and 407:
374Presynapticneuron11 107Neurotran
Page 408 and 409:
376SECTION IINEUROPHARMACOLOGYParav
Page 410 and 411:
(including penicillin and pentylene
Page 412 and 413:
380 (NMDA) receptors and non- NMDA
Page 414 and 415:
Table 14-4Subtypes of Muscarinic Re
Page 416 and 417:
384 thence to adenylyl cyclase. α
Page 418 and 419:
386HistamineNH 2HNNSECTION IIH 1 H
Page 420 and 421:
388β-LPHSignal peptideJP ACTH γ-L
Page 422 and 423:
390 Oglutamate (NMDA)-mediated neur
Page 425 and 426:
392 (e.g., ethanol) can exert relat
Page 427 and 428:
394 Bleich S, Romer K, Wiltfang J,
Page 429 and 430:
Page 431 and 432:
398 disease, especially myocardial
Page 433:
Page 437:
402Table 15-1Antidepressants: Chemi
Page 441 and 442:
404SECTION IINEUROPHARMACOLOGYanoth
Page 443 and 444:
Page 445 and 446:
408 antipsychotics are synergistic
Page 447 and 448:
410MAO to monoaminergic nerve termi
Page 449 and 450:
412SECTION IINEUROPHARMACOLOGYDrug
Page 451 and 452:
414SECTION IINEUROPHARMACOLOGYreupt
Page 453 and 454:
Page 455 and 456:
418 glutamate receptor. Advances in
Page 457 and 458:
420SECTION IINEUROPHARMACOLOGYPRESY
Page 459 and 460:
SECTION IINEUROPHARMACOLOGY422 Schi
Page 461:
424Table 16-1SECTION IINEUROPHARMAC
Page 465:
426Table 16-1Chemical Structures, D
Page 469 and 470:
428SECTION IINEUROPHARMACOLOGYantip
Page 471 and 472:
430SECTION IINEUROPHARMACOLOGYDA re
Page 473:
Page 477:
Page 480 and 481:
436 Absorption for most agents is q
Page 482 and 483:
438 seen, although they are less pr
Page 484 and 485:
440 health of the patient. Weight g
Page 486 and 487:
442 increased risk of sudden death
Page 488 and 489:
444 supporting data for certain anx
Page 490 and 491:
446 treatment with both Li + and va
Page 492 and 493:
448 therapeutic range (6-12 μg/mL)
Page 494 and 495:
450 Li + intoxication. Li + freely
Page 496 and 497:
452 Barten DM, Albright CF. Therape
Page 498 and 499:
454 Mahmoud RA, Pandina GJ, Turkoz
Page 500 and 501:
Page 502 and 503:
458 searches for agents with more s
Page 504 and 505:
460 by barbiturates and volatile an
Page 506 and 507:
462 a model in which benzodiazepine
Page 508 and 509:
Table 17-2Major Metabolic Relations
Page 510:
Page 513 and 514:
468SECTION IINEUROPHARMACOLOGYincid
Page 515:
Table 17-4Structures, Trade Names,
Page 518 and 519:
472SECTION IINEUROPHARMACOLOGYAbuse
Page 520 and 521:
474SECTION IINEUROPHARMACOLOGYenzym
Page 522 and 523:
476 Controversy in the management o
Page 524 and 525:
478 BIBLIOGRAPHYSECTION IINEUROPHAR
Page 526 and 527:
480 Twyman RE, Rogers CJ, Macdonald
Page 528 and 529:
482 the existence of three main rec
Page 530 and 531:
Table 18-1Actions and Selectivities
Page 532 and 533:
486SECTION IINEUROPHARMACOLOGYNocis
Page 534 and 535:
488 the receptor selectivity of the
Page 536 and 537:
490SECTION IINEUROPHARMACOLOGY(Sork
Page 538 and 539:
492SECTION IINEUROPHARMACOLOGYPrefr
Page 540 and 541:
494SECTION IINEUROPHARMACOLOGYindir
Page 542 and 543:
496SECTION IINEUROPHARMACOLOGYreser
Page 544:
Page 547 and 548:
500SECTION IINEUROPHARMACOLOGYaFigu
Page 549 and 550:
502SECTION IINEUROPHARMACOLOGYreact
Page 551 and 552:
504 may not do so with meperidine;
Page 553 and 554:
506 The use of fentanyl and sufenta
Page 555 and 556:
508 doses of 20-25 mg morphine give
Page 557 and 558:
510 of psychotomimetic side effects
Page 559 and 560:
512 syndrome in patients dependent
Page 561 and 562:
Table 18-3Epidural or Intrathecal O
Page 563 and 564:
516 significantly (Du Pen et al., 1
Page 565 and 566:
Routes of Administration Available.
Page 567 and 568:
question the accuracy of the diagno
Page 569 and 570:
522 Burkle H, Dunbar S, Van Aken H.
Page 571 and 572:
524 McIntosh M, Kane K, Parratt J.
Page 573 and 574:
Page 575 and 576:
528 asthmaticus with halothane and
Page 577 and 578:
Table 19-1Properties of Inhalationa
Page 579 and 580:
532 two-pore domain channels (Patel
Page 581:
534Table 19-2Pharmacological Proper
Page 584 and 585:
536 suppression of the EEG (Todd et
Page 586 and 587:
SECTION IINEUROPHARMACOLOGY538 Etom
Page 588 and 589:
Table 19-3Some Pharmacological Effe
Page 590 and 591:
542 and side-effect profiles. Halot
Page 592 and 593:
544 response to reduced blood press
Page 594 and 595:
546 nonflammable and non-explosive
Page 596 and 597:
548 anesthesia (Rasmussen et al., 2
Page 598 and 599:
550 few side effects. However, succ
Page 600:
Page 603 and 604:
554 effects on different organ syst
Page 605 and 606:
556 potential to promote absorption
Page 607 and 608:
558 CNS. Hypercarbia depresses the
Page 609 and 610:
560 of other gases, resulting in a
Page 611 and 612:
562 Grounds RM, Maxwell DL, Taylor
Page 613 and 614:
564 Taylor DR, Pijnenburg MW, Smith
Page 615 and 616:
566H 3 CO O CH 3C NOOC O H 2 NC OC
Page 617 and 618:
568Aβ 1 subunitα subunitNI II III
Page 619 and 620:
Table 20-1Susceptibility to Block T
Page 621 and 622:
572 such as methylparaben that may
Page 623 and 624:
574 complicates evaluation of the n
Page 625 and 626:
576 amount of cream that can be app
Page 627 and 628:
578 successful application of spina
Page 629 and 630:
580 intravascular injection easier
Page 631 and 632:
582 Yarov-Yarovoy V, McPhee JC, Ids
Page 633 and 634:
therapy. More detailed information
Page 635 and 636:
586SECTION IINEUROPHARMACOLOGYFigur
Page 637 and 638:
588OpenInactivatedNa + Na +vigabatr
Page 639 and 640:
590 The cellular electrophysiologic
Page 641 and 642:
Table 21-3Interactions of Anti-Seiz
Page 643 and 644:
594 These effects have been observe
Page 645 and 646:
596 Oxcarbazepine is a prodrug that
Page 647 and 648:
598 displacement of phenytoin from
Page 649 and 650:
600 explain lamotrigine’s actions
Page 651 and 652:
602 Pharmacological Effects and Mec
Page 653 and 654:
604 should not be taken lightly, be
Page 655 and 656:
606 of women with epilepsy have bee
Page 657 and 658:
Page 659 and 660:
610 excitotoxic injury, regional va
Page 661 and 662:
612SECTION IIPRESYNAPTIC TERMINALDi
Page 663 and 664:
Treatment of Parkinson DiseaseCommo
Page 665 and 666:
616 Levodopa therapy can have a dra
Page 667 and 668:
618 of levodopa/carbidopa. The acti
Page 669 and 670:
620 year to AD (Petersen et al., 20
Page 671 and 672:
622 potentially vagotonic propertie
Page 673 and 674:
624 designated IT15. It encodes a p
Page 675 and 676:
626Extrafusalmuscle fibersUppermoto
Page 677 and 678:
628 therapy for advanced Parkinson
Page 679 and 680:
630 (the “proof” of an alcoholi
Page 681 and 682:
632 methanol is taken along with et
Page 683 and 684:
634 2006). Acutely, ethanol results
Page 685 and 686:
636 atherogenesis (Chapter 31). Ano
Page 687 and 688:
638 pancreatitis has been known to
Page 689 and 690:
640 may occur with patients who app
Page 691 and 692:
642 termed fetal alcohol effects (F
Page 693 and 694:
644 metabolites of the drug, especi
Page 695 and 696:
646 Lemoine P, Harousseau H, Bortey
Page 697 and 698:
Page 699 and 700:
650 an addiction. These variables c
Page 701 and 702:
652 paucity of other options for pl
Page 703 and 704:
654 Withdrawal signs and symptoms o
Page 705 and 706:
656SECTION IINEUROPHARMACOLOGYA sig
Page 707 and 708:
Page 709 and 710:
660 crosses the blood-brain barrier
Page 711 and 712:
662 high school students has declin
Page 713 and 714:
664 developed and tested in control
Page 715 and 716:
666 demonstrated in humans, the cer
Page 717 and 718:
668 Mason BJ. Acamprosate and naltr
Page 719 and 720:
Page 721 and 722:
672Glomerulus1111210139(Outer Strip
Page 723 and 724:
674CCCCCCCCCCCCCBB1convectivesolute
Page 725 and 726:
676 7. As water and solutes accumul
Page 727 and 728:
Table 25-1Excretory and Renal Hemod
Page 729 and 730:
680 However, even with a high degre
Page 731 and 732:
682 Effects on Urinary Excretion. O
Page 733 and 734:
684SECTION IIIMODULATION OF CARDIOV
Page 735 and 736:
686 cardiac arrhythmias, particular
Page 737 and 738:
Table 25-5Inhibitors of Na + -Cl -
Page 739 and 740:
Thiazide diuretics decrease blood p
Page 741 and 742:
692 Pentamidine and high-dose trime
Page 743 and 744:
694ALATE DISTAL TUBULEAND COLLECTIN
Page 745 and 746:
696 channels are expressed in IMCD.
Page 747 and 748:
6981DIURETICSNa+ExcretionRateMABPMA
Page 749 and 750:
700ChronicrenalfailureNephroticsynd
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
706AVPAVPV 2β γα sAdenylylCyclas
Page 757 and 758:
708 antidiuretic response to vasopr
Page 759 and 760:
710 antidiuretic activity without i
Page 761 and 762:
Page 763 and 764:
714 Mild facial flushing and headac
Page 765 and 766:
Table 25-9Vasopressin Receptor Anta
Page 767 and 768:
718 Franse LV, Pahor M, Di Bari M,
Page 769 and 770:
Page 771 and 772:
722Angiotensinogen43 a.a. propeptid
Page 773 and 774:
724AGTAng I43 amino acidpropeptideA
Page 775 and 776:
726 in the locus p11.4 of the X chr
Page 777 and 778:
728 state, AngII may increase, decr
Page 779 and 780:
730 Normally, GFR is slightly reduc
Page 781 and 782:
Page 783 and 784:
734 metabolite, moexiprilat. Moexip
Page 785 and 786:
736 effective. Once ACE inhibitors
Page 787 and 788:
738 • ACE inhibitors may increase
Page 789 and 790:
(75-300 mg) reductions in blood pre
Page 791 and 792:
742 (LIFE): A randomized trial agai
Page 793 and 794:
744 Wallukat G, Homuth V, Fischer T
Page 795 and 796:
746Agents decreasing O 2 demandβ A
Page 797 and 798:
Table 27-1Organic Nitrates Availabl
Page 799 and 800:
750 consumption. An additional bene
Page 801 and 802:
752 angina when a nitrate-free inte
Page 803 and 804:
754 Transmucosal or Buccal Nitrogly
Page 805 and 806:
Table 27-2Ca 2+ Channel Blockers: C
Page 807 and 808:
758 increased modestly. After oral
Page 809 and 810:
760 Exertional Angina. Ca 2+ channe
Page 811 and 812:
Table 27-3Recommended Drug Therapy
Page 813 and 814:
764 a Ca 2+ channel blocker may pro
Page 815 and 816:
766 Hypertension is defined convent
Page 817 and 818:
Table 27-6Hemodynamic Effects of Lo
Page 819 and 820:
770 refractory to drugs that block
Page 821 and 822:
772 promotes endothelial cell depen
Page 823 and 824:
774 Methyldopa (α-methyl-3,4-dihyd
Page 825 and 826:
776 result of the lack of sympathet
Page 827 and 828:
778 normal renal function. However,
Page 829 and 830:
780 expression of hypoxia-inducible
Page 831 and 832:
782 ameliorated by a β receptor an
Page 833 and 834:
784 Stop Hypertension (DASH) diet m
Page 835 and 836:
786 Chaitman BR, Pepine CJ, Parker
Page 837 and 838:
788 Pedersen ME, Cockcroft JR. What
Page 839 and 840:
790 Congestive heart failure is the
Page 841 and 842:
792NormalCongestivesymptomsototoxic
Page 843 and 844:
794sympatheticstimulationBradykinin
Page 845 and 846:
Page 847 and 848:
798 counterproductive in symptomati
Page 849 and 850:
800 CHF and may represent one mecha
Page 851 and 852:
802 Mechanism of the Positive Inotr
Page 853 and 854:
804 recognition of digoxin toxicity
Page 855 and 856:
806Pressure (mm Hg)ESPVREDPVR(diast
Page 857 and 858:
808 acid level reduction (over 24 w
Page 859 and 860:
810 and management of end- stage CH
Page 861 and 862:
SECTION IIIMODULATION OF CARDIOVASC
Page 863 and 864:
Page 865 and 866:
816Na +0 mV -90 mV4 mM 150 mM0 mV -
Page 867 and 868:
818SA nodeAtriumAV nodePurkinje fib
Page 869 and 870:
820 MECHANISMS OF CARDIACARRHYTHMIA
Page 871 and 872:
822ADAD1accessorypathway2BEADSECTIO
Page 873 and 874:
Table 29-2A Mechanistic Approach to
Page 875 and 876:
826ABDecreasedphase 4slopeIncreased
Page 877 and 878:
828 better characterized in a range
Page 879 and 880:
830 nodal function permits a greate
Page 881 and 882:
832 many arrhythmias than other β
Page 883 and 884:
834 ANTI-ARRHYTHMIC DRUGSSECTION II
Page 886:
Table 29-5Pharmacokinetic Character
Page 889 and 890:
838 Pharmacologic Effects. Digitali
Page 891 and 892:
840 atrial fibrillation. However, d
Page 893 and 894:
842 fall. To avoid this distributio
Page 895 and 896:
Page 897 and 898:
846 initially tolerating antiarrhyt
Page 899 and 900:
848 Stewart RB, Bardy GH, Greene HL
Page 901 and 902:
850Endothelial cellsPlatelets+COX-1
Page 903 and 904:
852 formation of a superimposed thr
Page 905 and 906:
About 10-15 glycosaminoglycan chain
Page 907 and 908:
856AUnfractionedheparinFactorXaPent
Page 909 and 910:
858 For therapeutic purposes, hepar
Page 911 and 912:
860 Bivalirudin contains the sequen
Page 913 and 914:
862 with the functional level of pr
Page 915 and 916:
864 inhibits platelet function. Eld
Page 917 and 918:
866 Dabigatran etexilate is approve
Page 919 and 920:
868 indications as aminocaproic aci
Page 921 and 922:
870 for clopidogrel are to reduce t
Page 923 and 924:
872 approved, ticagrelor is the fir
Page 925 and 926:
874 has received anticoagulant or a
Page 927 and 928:
876 Varmus H, eds. The Molecular Ba
Page 929 and 930:
878 to as “small, dense LDL”) (
Page 932:
Page 935 and 936:
882 increasing triglyceride- and ch
Page 937 and 938:
884 Tangier disease, a genetic diso
Page 939 and 940:
Table 31-3Treatment Based on LDL-C
Page 941 and 942:
Table 31-6Assessing 10-Year Risk of
Page 943 and 944:
Page 945 and 946:
Treatment of HypertriglyceridemiaTh
Page 947 and 948:
894 Figure 31-2 along with the reac
Page 949 and 950:
896 Due to extensive first-pass hep
Page 951 and 952:
898 unless the patient also is taki
Page 953 and 954:
900 Niacin is a water-soluble B-com
Page 955 and 956:
902 Mechanism of Action. Despite ex
Page 957 and 958:
904 diminished remnant cholesterol
Page 959 and 960:
906 D’Agostino RB Sr, Vasan RS, P
Page 961 and 962:
908 Prueksaritanont T, Tang C, Qiu
Page 963 and 964:
Page 965 and 966:
912 antagonists has yet emerged as
Page 967 and 968:
914 Regulation of Mediator Release.
Page 969 and 970:
916 of H receptor subtypes on neigh
Page 971 and 972:
918 by H 2blockade. In asthmatic su
Page 973 and 974:
920 et al., 2002). Thus, the develo
Page 975 and 976:
Table 32-2Preparations and Dosage o
Page 977 and 978:
924 Ethylenediamines (Prototype: Py
Page 979 and 980:
926 Caution should be used in treat
Page 981 and 982:
Table 32-3Structure of Kinin Agonis
Page 983 and 984:
930Aminopeptidase PKininase I(Carbo
Page 985 and 986:
932 thrombin generation following c
Page 987 and 988:
934 Leeb-Lundberg LM, Marceau F, Mu
Page 989 and 990:
Page 991 and 992:
938SECTION IVINFLAMMATION, IMMUNOMO
Page 993 and 994:
Page 995 and 996:
942 cytoprotective PGs in the GI tr
Page 997 and 998:
of the TP (α and β), FP (A and B)
Page 999 and 1000:
946 receptors have limited distribu
Page 1001 and 1002:
948 dysfunctional ROMK2, also is kn
Page 1003 and 1004:
950 inflammation by increasing endo
Page 1005 and 1006:
952 ligands such as oxidized lipids
Page 1007 and 1008:
954 Physiological and Pathological
Page 1009 and 1010:
956 FitzGerald GA. Mechanisms of pl
Page 1011 and 1012:
Page 1013 and 1014:
960 face of environmental pathogens
Page 1015 and 1016:
962 endogenous pyrogens. The initia
Page 1017 and 1018:
964 COX-2, and thus COX-2-mediated
Page 1019:
Page 1023:
Page 1027:
970SECTION IVTable 34-1Classificati
Page 1030 and 1031:
972 However, low-dose aspirin is no
Page 1032 and 1033:
974 warfarin (12-fold), glucocortic
Page 1034 and 1035:
976 implicated in Reye’s syndrome
Page 1036 and 1037:
978 capillary permeability during i
Page 1038 and 1039:
980 after initiation of therapy is
Page 1040 and 1041:
982 result of three processes. Firs
Page 1042 and 1043:
984 Management of Acetaminophen Ove
Page 1044 and 1045:
986 Adverse Effects. Etodolac appea
Page 1046 and 1047:
Page 1048 and 1049:
990 After absorption, piroxicam is
Page 1050 and 1051:
992 attributable to COX-2-selective
Page 1052 and 1053:
Table 34-3Disease-Modifying Anti-Rh
Page 1054 and 1055:
996 year, and 0.6 mg two or three t
Page 1056 and 1057:
998 complex with both the reduced a
Page 1058 and 1059:
1000 refractory to other drugs used
Page 1060 and 1061:
1002 Davies NM, Anderson KE. Clinic
Page 1062 and 1063:
1004 Solomon SD, McMurray JJ, Pfeff
Page 1064 and 1065:
1006 the induction and maintenance
Page 1066 and 1067:
1008 other immunosuppressive agents
Page 1068 and 1069:
1010TCRSECTION IVINFLAMMATION, IMMU
Page 1070 and 1071:
1012 gout, increased P-glycoprotein
Page 1072 and 1073:
1014 common), and/or anemia (uncomm
Page 1074 and 1075:
1016 have overcome the problems of
Page 1076 and 1077:
1018 cyclosporine and prednisone. I
Page 1078 and 1079:
1020 trials. Because they remain ex
Page 1080 and 1081:
1022 with erythema nodosum leprosum
Page 1082 and 1083:
Table 35-2Selected Immune Globulin
Page 1084 and 1085:
agent that ameliorates auto-immune
Page 1086 and 1087:
1028 Eisen HJ, Tuzcu EM, Dorent R,
Page 1088 and 1089:
Page 1090 and 1091:
1032AllergenDendritic cellMast cell
Page 1092 and 1093:
1034 ROUTES OF DRUG DELIVERYTO THE
Page 1094 and 1095:
1036NOREPINEPHRINEHO CH CH 2 NH 2HO
Page 1096 and 1097:
1038 the treatment of asthma due to
Page 1098 and 1099:
1040 a marked increase in the risk
Page 1100 and 1101:
1042SECTION IVINFLAMMATION, IMMUNOM
Page 1102 and 1103:
1044 is the first drug to demonstra
Page 1104 and 1105:
1046 including glycopyrrolate and a
Page 1106 and 1107:
1048Inflammatory stimulie.g. IL-1β
Page 1108 and 1109:
1050 Routes of Administration and D
Page 1110 and 1111:
1052 lung function than if treatmen
Page 1112 and 1113:
1054 were not on concomitant cortic
Page 1114 and 1115:
1056 IL-4 and IL-13, which determin
Page 1116 and 1117:
1058 (Dicpinigaitis, 2009a). It can
Page 1118 and 1119:
1060AEndothelial factors influencin
Page 1120 and 1121:
1062 Clark AR. MAP kinase phosphata
Page 1122 and 1123:
1064 Nathani N, Little MA, Kunst H,
Page 1124 and 1125:
Page 1126 and 1127:
1068 Individual growth factors then
Page 1128 and 1129:
Table 37-1Hematopoietic Growth Fact
Page 1130 and 1131:
1072 estimated as ~17% based on a m
Page 1132 and 1133:
1074 reduced without a change in lo
Page 1134 and 1135:
1076 and many other organs. In both
Page 1136 and 1137:
1078 (IRP1 and IRP2). Double knocko
Page 1138 and 1139:
1080SECTION IVINFLAMMATION. IMMUNOM
Page 1140 and 1141:
1082 limits the entry of iron into
Page 1142 and 1143:
1084 follows usual oral doses. Comm
Page 1144 and 1145:
SECTION IVINFLAMMATION. IMMUNOMODUL
Page 1146 and 1147:
1088 methyl group to cobalamin is e
Page 1148 and 1149:
1090 intracellular storage proteins
Page 1150 and 1151:
1092 neurological signs or symptoms
Page 1152 and 1153:
1094 DIETLiverdisease and for venou
Page 1154 and 1155:
1096 seventh days; the reticulocyte
Page 1156 and 1157:
1098 Hoffbrand AV, Herbert V. Nutri
Page 1158 and 1159:
Page 1160 and 1161:
Page 1162 and 1163:
disorders. Chapters 38 through 44 d
Page 1164 and 1165:
Table 38-2Properties of the Protein
Page 1166 and 1167:
1108SECTION VHORMONES AND HORMONE A
Page 1168 and 1169:
1110AGHBGHGHPegvisomantGHRGHRGHRGHR
Page 1170 and 1171:
1112 Clinical Manifestations of Gro
Page 1172 and 1173:
1114 provides a highly effective al
Page 1174 and 1175:
1116 ZORBTIVE); somatrem refers to
Page 1176 and 1177:
Page 1179 and 1180:
1120 Gonadotropin production also i
Page 1181 and 1182:
1122 to therapeutic advantage in a
Page 1183 and 1184:
1124 detect the presence of an ecto
Page 1185 and 1186:
1126 CLINICAL SUMMARYSECTION VHORMO
Page 1187 and 1188:
Page 1189 and 1190:
1130 important role in energy metab
Page 1191 and 1192:
1132BasolateralmembraneApicalmembra
Page 1193 and 1194:
Table 39-1Properties of Iodothyroni
Page 1195 and 1196:
Page 1197 and 1198:
1138 whereas dairy products and fis
Page 1199 and 1200:
1140 it is the effects of unligande
Page 1201 and 1202:
1142 types of thyroid dysfunction,
Page 1203 and 1204:
1144 Subclinical Hypothyroidism. Su
Page 1205 and 1206:
1146 of patients and hence have lit
Page 1207 and 1208:
1148 have weak anti-thyroid action
Page 1209 and 1210:
1150 then the lower maintenance dos
Page 1211 and 1212:
1152 cigarette smoking has been rep
Page 1213 and 1214:
1154 Untoward Reactions. Occasional
Page 1215 and 1216:
1156 when prolonged treatment with
Page 1217 and 1218:
1158 Bartalena L, Marcocci C, Tanda
Page 1219 and 1220:
1160 combination of methimazole and
Page 1221 and 1222:
Page 1223 and 1224:
Page 1225 and 1226:
1166 Estrogens appear to play impor
Page 1227 and 1228:
1168AFOLLICULAR PHASELUTEAL PHASEBF
Page 1229 and 1230:
1170 Estrogens have positive effect
Page 1231 and 1232:
1172AERERTATAAAgonistEEGGTCAnnnTGAC
Page 1233 and 1234:
1174 FEMRING) may be used for slow
Page 1235 and 1236:
1176 population continues to age. O
Page 1237 and 1238:
1178 Tamoxifen is a triphenylethyle
Page 1239 and 1240:
1180 increase the risk of ovarian c
Page 1241 and 1242:
1182 with the fetal adrenal glands,
Page 1243 and 1244:
1184 Therapeutic UsesThe two most f
Page 1245 and 1246:
1186 capacity to supply food, energ
Page 1247 and 1248:
1188 events in women without other
Page 1249 and 1250:
1190 is discontinued. These agents
Page 1251 and 1252:
1192 Grumbach MM, Auchus RJ. Estrog
Page 1253 and 1254:
1194 Van Den Bemd GJ, Kuiper GG, Po
Page 1255 and 1256:
119621H 3 C 20H 3 C1711CH 3side cha
Page 1257 and 1258:
1198 (Gln) 20 (Pro) 8 (Gly) 23 arom
Page 1259 and 1260:
1200 After Completion of Puberty. W
Page 1261 and 1262:
1202 ATestosterone Enanthateenjoyed
Page 1263 and 1264:
1204 Side Effects. All androgens su
Page 1265 and 1266:
1206 to dihydrotestosterone, which
Page 1267 and 1268:
Page 1269 and 1270:
1210 the role of the hypothalamus i
Page 1271 and 1272:
1212CYP11A1HOH 3 CH 3 CH 3 C11C8B19
Page 1273 and 1274:
1214 G q-PLC-IP 3-Ca 2+ pathway to
Page 1275 and 1276:
of corticosteroids—one of the maj
Page 1277 and 1278:
1218 to the nucleus. There, it inte
Page 1279 and 1280:
1220 effect of other agents, such a
Page 1281 and 1282:
suppression of inflammation is of e
Page 1283 and 1284:
1224 (e.g., corticosterone) have ap
Page 1285 and 1286:
Table 42-4Available Preparations of
Page 1287 and 1288:
1228 and error and must be the lowe
Page 1289 and 1290:
1230 mineralocorticoid used is flud
Page 1291 and 1292:
1232 Ocular Diseases. Ocular pharma
Page 1293 and 1294:
1234 and 11-deoxycortisol are measu
Page 1295 and 1296:
Page 1297 and 1298:
1238A Fasting state B Prandial stat
Page 1299 and 1300:
1240 interplay of various nutrients
Page 1301 and 1302:
1242SECTION VInsulinreceptorαβY-S
Page 1303 and 1304:
Table 43-2Different Forms of Diabet
Page 1305 and 1306:
1246 fasting. Beyond the defect in
Page 1307 and 1308:
1248 Therapy of DiabetesSECTION VHO
Page 1309 and 1310:
Commercial preparations of insulin
Page 1311 and 1312:
1252 which stabilizes the insulin h
Page 1313 and 1314:
1254 new cases of pediatric diabete
Page 1315 and 1316:
Table 43-7Structural Formulas of th
Page 1317 and 1318:
Nateglinide is metabolized primaril
Page 1319 and 1320:
1260 and their specific role in the
Page 1321 and 1322:
1262ProglucagonGRPP Glucagon IP-1 G
Page 1323 and 1324:
1264 DPP-4 InhibitorsMechanism of A
Page 1325 and 1326:
Page 1327:
Page 1331 and 1332:
1270 system that prevents acute hyp
Page 1333 and 1334:
1272 Concannon P, Rich SS, Nepom GT
Page 1335 and 1336:
Page 1337 and 1338:
12761092.5Intestine:800 mg intakeBo
Page 1339 and 1340:
1278 removed by extrarenal mechanis
Page 1341 and 1342:
1280 response to positive or negati
Page 1343 and 1344:
Page 1345 and 1346:
1284Calcitonin/katacalcin/CGRPgene5
Page 1347 and 1348:
1286Bone lining cellsBoneOsteoclast
Page 1349 and 1350:
1288 25-hydroxy- and 1,25-dihydroxy
Page 1351 and 1352:
1290 deposition in bone, once a cau
Page 1353 and 1354:
1292OHSECTION VHOOH1OHD 3alphacalci
Page 1355 and 1356:
1294 uses of vitamin D are discover
Page 1357 and 1358:
1296 has been supplanted largely by
Page 1359 and 1360:
1298 cinacalcet improves outcomes s
Page 1361 and 1362:
1300 cancer, and coronary events (c
Page 1363 and 1364:
1302 enamel. Osteosclerosis is char
Page 1365 and 1366:
1304 Greenspan SL, Bone HG, Ettinge
Page 1367 and 1368:
1306 Van Cromphaut SJ, Dewerchin M,
Page 1369 and 1370:
Page 1371 and 1372:
1310GastrinMuscarinicantagonistsSEC
Page 1373 and 1374:
1312 • enteric-coated granules su
Page 1375 and 1376:
1314 within 1-3 hours. Absorption m
Page 1377 and 1378:
Table 45-2Composition and Acid Neut
Page 1379 and 1380:
1318Severity of GERDStage ISporadic
Page 1381 and 1382:
1320 that H. pylori plays a major e
Page 1383 and 1384:
1322 Norgard NB, Mathews KD, Wall G
Page 1385 and 1386:
1324ORAL4ANALLM26135+ + - - -7MPCMS
Page 1387 and 1388:
1326 Metoclopramide is available in
Page 1389 and 1390:
1328 undigested food into the small
Page 1391 and 1392:
The terms laxatives, cathartics, pu
Page 1393 and 1394:
1332SECTION VIDRUGS AFFECTING GASTR
Page 1395 and 1396:
1334 have been used as laxatives. A
Page 1397 and 1398:
1336 sodium bicarbonate and potassi
Page 1399 and 1400:
1338 Loperamide N-oxide, an investi
Page 1401 and 1402:
1340 involvement in sensitization o
Page 1403 and 1404:
HIGHERCENTERSMemory, fear,dread, an
Page 1405 and 1406:
1344 AntihistaminesTable 46-7SECTIO
Page 1407 and 1408:
1346 component of nausea and vomiti
Page 1409 and 1410:
1348 options. For patients with gas
Page 1411 and 1412:
Page 1413:
1352SECTION VIDRUGS AFFECTING GASTR
Page 1416 and 1417:
1354 mediated inflammatory processe
Page 1418 and 1419:
1356 rapid acetylators have lower s
Page 1420 and 1421:
1358 liver function tests also may
Page 1422 and 1423:
1360 for the treatment of Crohn’s
Page 1424 and 1425:
1362 Prantera C, Cottone M, Pallone
Page 1426 and 1427:
Page 1428 and 1429:
1366SECTION VIICHEMOTHERAPY OF MICR
Page 1430 and 1431:
1368Absorption compartment (p)SECTI
Page 1432 and 1433:
Page 1434 and 1435:
1372 Third, optimal microbial kill
Page 1436 and 1437:
1374 colonization or infection by a
Page 1438 and 1439:
1376 penicillin that resistance dev
Page 1440 and 1441:
1378 or by subsequent transfers to
Page 1442 and 1443:
1380 Lewis K. Riddle of biofilm res
Page 1444 and 1445:
Page 1446 and 1447:
1384 hepatocyte infection as a dorm
Page 1448 and 1449:
Table 49-1Malarial Parasite Develop
Page 1450 and 1451:
Table 49-2Regimens for the Preventi
Page 1453:
Page 1457:
Page 1461:
Page 1464 and 1465:
1396 site. Both artesunate and arte
Page 1466 and 1467:
1398 recent study reported an incre
Page 1468 and 1469:
1400 The 2,4-diaminopyrimidines mor
Page 1470 and 1471:
1402 chloroquine and pyrimethamine-
Page 1472 and 1473:
1404 By studying the progeny of a g
Page 1474 and 1475:
1406 Chemistry. Cinchona contains a
Page 1476 and 1477:
1408 MefloquineSECTION VIICHEMOTHER
Page 1478 and 1479:
1410 Therapeutic or higher doses of
Page 1480 and 1481:
In general, dosing should be starte
Page 1482 and 1483:
1414 For clinical classification of
Page 1484 and 1485:
1416 Bray PG, Ward SA, O’Neill PM
Page 1486 and 1487:
1418 Valderramos SG, Fidock DA. Tra
Page 1488 and 1489:
1420 The organisms can be different
Page 1490 and 1491:
1422 African (Gambian), caused by T
Page 1492 and 1493:
1424 Isospora belli, a coccidian pa
Page 1494 and 1495:
1426 nifurtimox used in combination
Page 1496 and 1497:
1428 encephalopathy (the treatment-
Page 1498 and 1499:
1430 elapse between courses. In suc
Page 1500 and 1501:
1432 T. brucei and can be curative
Page 1502 and 1503:
1434 whereas children have been tre
Page 1504 and 1505:
1436 2006), where lipid-based ampho
Page 1506 and 1507:
1438 stomatitis, chills, abdominal
Page 1508 and 1509:
1440 surveillance study in HIV-infe
Page 1510 and 1511:
Page 1512 and 1513:
Page 1514 and 1515:
1446 hyperinfection. Ivermectin is
Page 1516 and 1517:
1448 Diphyllobothrium latum. Diphyl
Page 1518 and 1519:
Page 1520 and 1521:
1452 with combination therapy for 4
Page 1522 and 1523:
1454 (Addiss and Dreyer, 2000). Exp
Page 1524 and 1525:
1456 ivermectin (Molyneux et al., 2
Page 1526 and 1527:
1458 bioavailability of praziquante
Page 1528 and 1529:
1460 Dull HB, Meredith SE. The Mect
Page 1530 and 1531:
Page 1532 and 1533:
Page 1534 and 1535:
1466 readily than the free fraction
Page 1536 and 1537:
1468 Aplastic Anemia. Complete supp
Page 1538 and 1539:
1470 anti-Pneumocystis therapy in p
Page 1540 and 1541:
1472 DNA via an ATP-dependent react
Page 1542 and 1543:
1474 were also receiving theophylli
Page 1544 and 1545:
1476 Centers for Disease Control an
Page 1546 and 1547:
1478 was that of a policeman who wa
Page 1548 and 1549:
1480AGram positiveGram negativeSECT
Page 1550 and 1551:
1482 Classification of the Penicill
Page 1552 and 1553:
1484 1.5 million units every 8-12 h
Page 1554 and 1555:
1486 under controlled conditions, i
Page 1556 and 1557:
Table 53-1Chemical Structures and M
Page 1558 and 1559:
1490 increasingly common. Enterococ
Page 1560 and 1561:
1492 Serum sickness varies from mil
Page 1562 and 1563:
Table 53-2Names, Structural Formula
Page 1564 and 1565:
Table 53-3Cephalosporin Generations
Page 1566 and 1567:
1498 microorganisms than is the par
Page 1568 and 1569:
1500 Imipenem. Imipenem is marketed
Page 1570 and 1571:
1502 Brown EJ. The molecular basis
Page 1572 and 1573:
Page 1574 and 1575:
1506ACAC IAC IIAC IIIACAC IAC IIAC
Page 1576 and 1577:
Page 1578 and 1579:
1510 wounds, burns, or cutaneous ul
Page 1580 and 1581:
1512 (Knoderer et al., 2003; Rastog
Page 1582 and 1583:
1514 of the collecting-duct epithel
Page 1584 and 1585:
1516 vancomycin has been recommende
Page 1586 and 1587:
1518 Prophylactic Uses. Kanamycin c
Page 1588 and 1589:
1520 Luzzatto L, Apirion D, Schless
Page 1590 and 1591:
Table 55-1Structural Formulas of th
Page 1592 and 1593:
1524 Oral doses of doxycycline and
Page 1594 and 1595:
1526 Photosensitivity. Demeclocycli
Page 1596 and 1597:
1528 less toxic and because strains
Page 1598 and 1599:
1530 In general, organisms are cons
Page 1600 and 1601:
1532 failure. No dose has been esta
Page 1602 and 1603:
1534 gastric emptying in patients w
Page 1604 and 1605:
1536 streptogramin A, in a 30:70 ra
Page 1606 and 1607:
1538 Indiscriminant use and overuse
Page 1608 and 1609:
1540 Antimicrobial Activity. Vancom
Page 1610 and 1611:
1542 because these modalities clear
Page 1612 and 1613:
1544 dermal ulcers, the local appli
Page 1614 and 1615:
1546 review of the published eviden
Page 1616 and 1617:
Page 1618 and 1619:
Page 1620 and 1621:
Page 1622 and 1623:
1554 Rifamycin Overdose. Rifampin o
Page 1624 and 1625:
1556 Other products of KatG activat
Page 1626 and 1627:
appear during the use of this drug,
Page 1628 and 1629:
1560 ClofazimineClofazimine (LAMPRE
Page 1630 and 1631:
1562 acid synthase II (Larsen et al
Page 1632 and 1633:
1564 Anti-parasitic. Dapsone is als
Page 1634 and 1635:
1566 Therapy of MAC Pulmonary Infec
Page 1636 and 1637:
Page 1638 and 1639:
1570 Orenstein EW, Basu S, Shah NS,
Page 1640 and 1641:
Page 1642 and 1643:
Table 57-2Pharmocokinetic Parameter
Page 1644 and 1645:
1576 with cryptococcosis, but the c
Page 1646 and 1647:
Table 57-6Some Additional Contraind
Page 1648 and 1649:
1580 excretion accounts for >90% of
Page 1650 and 1651:
1582 13 days. Posaconazole is appro
Page 1652 and 1653:
1584 Metabolism and Excretion. Cata
Page 1654 and 1655:
1586 and severe angioedema develop
Page 1656 and 1657:
1588 Oxiconazole, Sulconazole, and
Page 1658 and 1659:
1590 De Pauw BE, Donnelly JP. Proph
Page 1660 and 1661:
Page 1662 and 1663:
Table 58-1Stages of Virus Replicati
Page 1664 and 1665:
Table 58-2Nomenclature of Antiviral
Page 1666 and 1667:
1598HerpessimplexCytoplasmSECTION V
Page 1668 and 1669:
1600 and adults. In children weighi
Page 1670 and 1671:
1602 Absorption, Distribution, and
Page 1672 and 1673:
1604 and Faulds, 1998). Inhibitory
Page 1674 and 1675:
Page 1676 and 1677:
1608 amantadine or rimantadine trea
Page 1678 and 1679:
1610 without known airway disease,
Page 1680 and 1681:
Page 1682 and 1683:
Page 1684 and 1685:
1616 anti-HBV nucleosides show enha
Page 1686 and 1687:
1618 ≥41% of patients, and reduct
Page 1688 and 1689:
1620 De Clercq E. Clinical potentia
Page 1690 and 1691:
1622 for cytomegalovirus retinitis
Page 1692 and 1693:
1624 clade per se does not seem to
Page 1694 and 1695:
1626 control but also complicates t
Page 1696 and 1697:
1628 Failure of an antiretroviral r
Page 1698:
Page 1701 and 1702:
1632 eliminated from the body prima
Page 1703 and 1704:
1634 accumulate in the cell, and th
Page 1705 and 1706:
1636 Carbovir, a related guanine an
Page 1707 and 1708:
1638 atazanavir increases the tenof
Page 1709 and 1710:
1640 generally can be avoided by se
Page 1711 and 1712:
Table 59-3Pharmacokinetic Propertie
Page 1713 and 1714:
1644 effective in patients who have
Page 1715 and 1716:
1646SECTION VIINOHNH 2 NONHOOHONHNH
Page 1718 and 1719:
Page 1720 and 1721:
1650 the low doses used for this pu
Page 1722 and 1723:
1652 diarrhea, nausea, and vomiting
Page 1724 and 1725:
1654 In treatment-naive patients re
Page 1726 and 1727:
1656 tipranavir/ritonavir or a comp
Page 1728 and 1729:
1658 with an intravenous dose (Dand
Page 1730 and 1731:
1660 In each of these settings, the
Page 1732 and 1733:
1662 Jayasekara D, Aweeka FT, Rodri
Page 1734 and 1735:
Page 1736 and 1737:
Page 1738 and 1739:
Table 60-1Alkylating AgentsNONPROPR
Page 1740 and 1741:
Table 60-4Hormones and AntagonistsN
Page 1742 and 1743:
1672SECTION VIIICHEMOTHERAPY OF NEO
Page 1744 and 1745:
1674 employed in traditional cytoto
Page 1746 and 1747:
Page 1748 and 1749:
Page 1750 and 1751:
Page 1752 and 1753:
is reversible at usual doses, but o
Page 1754 and 1755:
1684 However, adequate hydration an
Page 1756 and 1757:
1686 fall for >1 month after discon
Page 1758 and 1759:
1688 platinum complexes do not form
Page 1760 and 1761:
1690 intravenously and decline ther
Page 1762 and 1763:
1692Pteridine ringp-aminobenzoic ac
Page 1764 and 1765:
1694 four doses, alternating with l
Page 1766 and 1767:
1696Fluoropyrimidine AnalogsH 3 COH
Page 1768 and 1769:
1698 Intrahepatic arterial infusion
Page 1770 and 1771:
1700 the liposomal formulation is i
Page 1772 and 1773:
1702 de novo purine synthesis and a
Page 1774 and 1775:
1704 Cladribine is considered the d
Page 1776 and 1777:
1706 throughout the cytoplasm (expl
Page 1778 and 1779:
1708 prior to therapy is required t
Page 1780 and 1781:
1710 1.6 months with ixabepilone pl
Page 1782 and 1783:
1712 The recommended dosing regimen
Page 1784 and 1785:
1714 As discussed in “Drug Resist
Page 1786 and 1787:
1716 compromised renal function, do
Page 1788 and 1789:
1718 basilar infiltrates on X-ray a
Page 1790 and 1791:
1720 double-strand DNA breaks throu
Page 1792 and 1793:
1722 is a potent radiosensitizer as
Page 1794 and 1795:
1724 core, allowing access for tran
Page 1796 and 1797:
1726 resistance against anticancer
Page 1798 and 1799:
1728 reductase activity contributes
Page 1800 and 1801:
1730 Westerhof GR, Rijnboutt S, Sch
Page 1802 and 1803:
Page 1804 and 1805:
1734 imatinib, as a competitive CYP
Page 1806 and 1807:
1736 Mechanism of Action. Erlotinib
Page 1808 and 1809:
1738 ErbB1 and ErbB2 and bind to an
Page 1810 and 1811:
1740 In colon cancer patients, colo
Page 1812 and 1813:
1742 and rapidly interconverting no
Page 1814 and 1815:
1744OHOcellmembraneIGF1ROther TK re
Page 1816 and 1817:
Table 62-1Monoclonal Antibodies App
Page 1818 and 1819:
1748 from the site targeted by ritu
Page 1820 and 1821:
1750 good performance status and no
Page 1822 and 1823:
1752 patients with CD33-positive ac
Page 1824 and 1825:
Page 1826 and 1827:
Page 1828 and 1829:
1758ONCH 3CH 3CH 3 O CH 3NSECTION V
Page 1830 and 1831:
1760 Steady-state concentrations ar
Page 1832 and 1833:
1762 administered once daily for 28
Page 1834 and 1835:
1764SECTION VIIICHEMOTHERAPY AND TA
Page 1837 and 1838:
1766 Available Anti-Androgens. Anti
Page 1839 and 1840:
1768 cancer in postmenopausal women
Page 1841 and 1842:
Page 1843 and 1844:
Page 1845 and 1846:
1774Superior oblique muscleLevator
Page 1847 and 1848:
1776SECTION IXSPECIAL SYSTEMS PHARM
Page 1849 and 1850:
covered by an episcleral vascular c
Page 1851 and 1852:
1780 Transcorneal and transconjunct
Page 1853 and 1854:
1782 The more commonly reported inf
Page 1855 and 1856:
Table 64-6Antifungal Agents for Oph
Page 1857 and 1858:
Table 64-7Autonomic Drugs for Ophth
Page 1859 and 1860:
1788 Such combinations reduce the n
Page 1861 and 1862:
1790 subconjunctivally during the p
Page 1863 and 1864:
Page 1865 and 1866:
1794 myopia and presumed ocular his
Page 1867 and 1868:
ACH 3CH 3C 7 10 151 H 2 C 6 C CH CH
Page 1869 and 1870:
1798 and reduce the synthesis of ot
Page 1871 and 1872:
1800 Fluorouracil Filtering Surgery
Page 1873 and 1874:
Page 1875 and 1876:
1804Shunt diffusionPermeationPenetr
Page 1877 and 1878:
Page 1879 and 1880:
Table 65-3Potency of Selected Topic
Page 1881 and 1882:
Table 65-4Topical RetinoidsRECEPTOR
Page 1883 and 1884:
Page 1885 and 1886:
Table 65-6Photochemotherapy Methods
Page 1887 and 1888:
Table 65-7Half-Life of Antihistamin
Page 1889 and 1890:
Page 1891 and 1892:
1820 CYTOTOXIC AND IMMUNOSUPPRESSIV
Page 1893 and 1894:
1822 Tacrolimus. Tacrolimus (FK506,
Page 1895 and 1896:
1824 An initial dosage of 50 mg/day
Page 1897 and 1898:
1826EpidermisNon-lesional skinAntig
Page 1899 and 1900:
evokes the same reaction on skin wi
Page 1901 and 1902:
Page 1903 and 1904:
1832 Repka-Ramirez MS, Baraniuk JN.
Page 1905 and 1906:
1834SECTION IXTable 66-1One-Year Fa
Page 1907 and 1908:
Table 66-2Brand Names and Formulati
Page 1909 and 1910:
1838 sex steroid hormones; are used
Page 1911 and 1912:
1840 Finally, some clinicians use a
Page 1913 and 1914:
Page 1915 and 1916:
1844A.Gonadotropin (IU)757575757575
Page 1917 and 1918:
1846 In pregnant women, the placent
Page 1919 and 1920:
1848 Although incompletely understo
Page 1921 and 1922:
1850 cesarean section in labor indu
Page 1923 and 1924:
1852 Olive DL. Gonadotropin-releasi
Page 1925 and 1926:
Page 1927 and 1928:
Table 67-1Examples of Important Car
Page 1929 and 1930:
Table 67-2Chemopreventive Agents Be
Page 1931 and 1932:
1860 Carcinogenicity. The primary c
Page 1933 and 1934:
1862 type (ATSDR, 2007b; Levin et a
Page 1935 and 1936:
1864BLOOD LEAD (μg/dL)Children Adu
Page 1937 and 1938:
1866 divalent (mercuric, Hg 2+ ) an
Page 1939 and 1940:
1868AFairbanks,AlaskaSECTION IXAleu
Page 1941 and 1942:
1870 Skin. The skin is very sensiti
Page 1943 and 1944:
1872 sulfate and phosphate and can
Page 1945 and 1946:
1874 appearance of chills and fever
Page 1947 and 1948:
Page 1949 and 1950:
1878 development of hepatocellular
Page 1951 and 1952:
1880APPENDIX ISuperscriptionPRINCIP
Page 1953 and 1954:
1882APPENDIX IPRINCIPLES OF PRESCRI
Page 1955 and 1956:
1884 >750 pairs of potentially conf
Page 1957 and 1958:
1886 if available. The USP maintain
Page 1959 and 1960:
1888 negative impact, that the ther
Page 1961 and 1962:
Page 1963 and 1964:
1892 has been selected from the lit
Page 1965 and 1966:
1894 To be accurate, clearances mus
Page 1967 and 1968:
1896 sustained-release product. Ind
Page 1969 and 1970:
1898 Because t 1/2has been the para
Page 1972:
1900APPENDIX IIDESIGN AND OPTIMIZAT
Page 1976:
Page 1980:
Page 1984:
Page 1988:
Page 1992:
Page 1996:
Page 2000:
Page 2004:
Page 2008:
Page 2012:
Page 2016:
Page 2020:
Page 2024:
Page 2028:
Page 2032:
Page 2036:
Page 2040:
Page 2044:
Page 2048:
Page 2052:
Page 2056:
Page 2060:
Page 2064:
Page 2068:
Page 2072:
Page 2076:
Page 2080:
Page 2084:
Page 2088:
Page 2092:
Page 2096:
Page 2100:
Page 2104:
Page 2108:
Page 2112:
Page 2116:
Page 2120:
Page 2124: 1976APPENDIX IIDESIGN AND OPTIMIZAT
Page 2155 and 2156: 1992INDEXAcetohexamide, 1257tAcetyl
Page 2157 and 2158: 1994INDEXAlendronate, pharmacokinet
Page 2159 and 2160: 1996INDEXAnalgesia/analgesics (Cont
Page 2161 and 2162: 1998INDEXAnthracyclines, 1713-1715l
Page 2163 and 2164: 2000INDEXAntioxidants, for pulmonar
Page 2165 and 2166: 2002INDEXAtorvastatin (Cont.):dosag
Page 2167 and 2168: 2004INDEXBenztropine, as antidote,
Page 2169 and 2170: 2006INDEXBortezomib (Cont.):mechani
Page 2171: 2008INDEXCAPOTEN (captopril), 732-7
Page 2175 and 2176: 2012INDEXChurg-Strauss angiitis,cyc
Page 2177 and 2178: 2014INDEXCompound 48/80, histamine
Page 2179 and 2180: 2016INDEXCytochrome P450CYP3A4, 897
Page 2181 and 2182: 2018INDEXDiabetes mellitus (DM) (Co
Page 2183 and 2184: 2020INDEXDiuretics (Cont.):inhibito
Page 2185 and 2186: 2022INDEXDYRENIUM (triamterene), 69
Page 2187 and 2188: 2024INDEXEpidermisand cutaneous dru
Page 2189 and 2190: 2026INDEXEtretinate (Cont.):standar
Page 2191 and 2192: 2028INDEXFlumazenil, 468-469, 1059a
Page 2193 and 2194: 2030INDEXGELUSIL II, 1316tGemcitabi
Page 2195 and 2196: 2032INDEXGynecology, drug therapy i
Page 2197 and 2198: 2034INDEXHistamine H 1receptor anta
Page 2199 and 2200: 2036INDEXHypobetalipoproteinemia, 8
Page 2201 and 2202: 2038INDEXInsulin (Cont.):as antidot
Page 2203 and 2204: 2040INDEXKKallidin, 926-932, 927f[d
Page 2205 and 2206: 2042INDEXLice, 1818-1819Lichen plan
Page 2207 and 2208: 2044INDEXLymphoma(s), 1755drugs for
Page 2209 and 2210: 2046INDEXMetabolism of drugs (Cont.
Page 2211 and 2212: 2048INDEXMisuse, poisoning and, 80M
Page 2213 and 2214: 2050INDEXMyocardial oxygen supply,p
Page 2215 and 2216: 2052INDEXNeurotransmitters (Cont.):
Page 2217 and 2218: 2054INDEXNorepinephrine, 287-288adv
Page 2219 and 2220: 2056INDEXOral contraceptives (Cont.
Page 2221 and 2222: 2058INDEXParturitioneicosanoids and
Page 2223 and 2224:
2060INDEXPhenytoin (Cont.):hypoglyc
Page 2225 and 2226:
2062INDEXPolymyxins, 1538-1539Polyt
Page 2227 and 2228:
2064INDEXPropidium, 241PROPINE (epi
Page 2229 and 2230:
2066INDEXQT interval, prologation,
Page 2231 and 2232:
2068INDEXRenin inhibitors, direct (
Page 2233 and 2234:
2070INDEXSalivary secretion, muscar
Page 2235 and 2236:
2072INDEXSmooth muscleamphetamines
Page 2237 and 2238:
2074INDEXSucralfateadverse effects
Page 2239 and 2240:
2076INDEXTenecteplase, 866Teniposid
Page 2241 and 2242:
2078INDEXTOLINASE (tolazamide), 125
Page 2243 and 2244:
2080INDEXTrospium chloride, 231, 23
Page 2245 and 2246:
2082INDEXVecuroniumcharacteristics
Page 2247:
2084INDEXXXALATAN (latanoprost), 17
show all

DƯỢC LÍ Goodman &amp; Gilman&#039;s The Pharmacological Basis of Therapeutics 12th, 2010

Create successful ePaper yourself

Delete template?

Save as template?

DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010